A groundbreaking international clinical trial has found that semaglutide—a medication widely used in managing type 2 diabetes and obesity—may also play a critical role in reversing liver damage in
Argus Research has reiterated a ‘Buy’ recommendation for Novo Nordisk (NVO), setting a target price of $140, which indicates a potential upside from its current trading price of $107.
